Pharmacokinetics of methylphenidate and ritalinic acid in plasma correlations with exhaled breath and oral fluid in healthy volunteers
暂无分享,去创建一个
[1] H. Rasmussen,et al. The impact of human CES1 genetic variation on enzyme activity assessed by ritalinic acid/methylphenidate ratios , 2019, Basic & clinical pharmacology & toxicology.
[2] Sudha R. Raman,et al. Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. , 2018, The lancet. Psychiatry.
[3] Matthias J. Müller,et al. TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians* , 2018, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[4] O. Beck,et al. A liquid chromatography and tandem mass spectrometry method to determine 28 non‐volatile drugs of abuse in exhaled breath , 2018, Journal of pharmaceutical and biomedical analysis.
[5] K Domschke,et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017 , 2017, Pharmacopsychiatry.
[6] P. Gustafsson,et al. Methylphenidate for Treating ADHD: A Naturalistic Clinical Study of Methylphenidate Blood Concentrations in Children and Adults With Optimized Dosage , 2016, European Journal of Drug Metabolism and Pharmacokinetics.
[7] E. Molden,et al. Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype , 2016, Therapeutic drug monitoring.
[8] T. Banaschewski,et al. An evaluation of the pharmacokinetics of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder , 2014, Expert opinion on drug metabolism & toxicology.
[9] R. Malmström,et al. Therapeutic drug monitoring for tomorrow , 2013, European Journal of Clinical Pharmacology.
[10] Olof Beck,et al. Detection of drugs of abuse in exhaled breath using a device for rapid collection: comparison with plasma, urine and self-reporting in 47 drug users , 2013, Journal of breath research.
[11] J. V. van Gerven,et al. Determination of methylphenidate in plasma and saliva by liquid chromatography/tandem mass spectrometry. , 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[12] A. Straughn,et al. Differential Influences of Ethanol on Early Exposure to Racemic Methylphenidate Compared with Dexmethylphenidate in Humans , 2013, Drug Metabolism and Disposition.
[13] H. Rasmussen,et al. Enantioselective determination of methylphenidate and ritalinic acid in whole blood from forensic cases using automated solid-phase extraction and liquid chromatography-tandem mass spectrometry. , 2012, Journal of analytical toxicology.
[14] M. Josefsson,et al. Determination of methylphenidate and ritalinic acid in blood, plasma and oral fluid from adolescents and adults using protein precipitation and liquid chromatography tandem mass spectrometry--a method applied on clinical and forensic investigations. , 2011, Journal of pharmaceutical and biomedical analysis.
[15] Yong Zhang,et al. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel , 2010, Comput. Methods Programs Biomed..
[16] J. Franck,et al. Method for determination of methadone in exhaled breath collected from subjects undergoing methadone maintenance treatment. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[17] M. Farré,et al. Correlation between methylphenidate and ritalinic acid concentrations in oral fluid and plasma. , 2010, Clinical chemistry.
[18] S. Bálint,et al. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis , 2009, British Journal of Psychiatry.
[19] J. Lausmaa,et al. Airway monitoring by collection and mass spectrometric analysis of exhaled particles. , 2009, Analytical chemistry.
[20] E. Gallardo,et al. The role of alternative specimens in toxicological analysis. , 2008, Biomedical chromatography : BMC.
[21] Julie A. Johnson,et al. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. , 2008, American journal of human genetics.
[22] J. Markowitz,et al. Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? , 2008, Journal of clinical psychopharmacology.
[23] B. Horta,et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. , 2007, The American journal of psychiatry.
[24] Carol A. Perlman,et al. Medication Adherence in Psychopharmacologically Treated Adults With ADHD , 2007, Journal of attention disorders.
[25] S. Pliszka,et al. Pharmacologic Treatment of Attention-Deficit/Hyperactivity Disorder: Efficacy, Safety and Mechanisms of Action , 2007, Neuropsychology Review.
[26] Olaf H Drummer,et al. Drug testing in oral fluid. , 2006, The Clinical biochemist. Reviews.
[27] D. Murry,et al. Methylphenidate Is Stereoselectively Hydrolyzed by Human Carboxylesterase CES1A1 , 2004, Journal of Pharmacology and Experimental Therapeutics.
[28] A. Straughn,et al. Advances in the Pharmacotherapy of Attention‐Deficit‐Hyperactivity Disorder: Focus on Methylphenidate Formulations , 2003, Pharmacotherapy.
[29] A. Avenoso,et al. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone , 1999, Psychopharmacology.
[30] D. Parmelee,et al. Population Pharmacokinetics of Methylphenidate in Children with Attention‐Deficit Hyperactivity Disorder , 1999, Journal of clinical pharmacology.
[31] G. Breese,et al. Pharmacology of the enantiomers of threo-methylphenidate. , 1987, The Journal of pharmacology and experimental therapeutics.
[32] J. Perel,et al. Metabolism and disposition of methylphenidate-14C: studies in man and animals. , 1974, The Journal of pharmacology and experimental therapeutics.
[33] J. Franck,et al. Drug abuse screening with exhaled breath and oral fluid in adults with substance use disorder. , 2019, Drug testing and analysis.
[34] O. Beck,et al. Clinical trial of a new technique for drugs of abuse testing: a new possible sampling technique. , 2015, Journal of substance abuse treatment.
[35] D. Heal,et al. Methylphenidate and its Isomers , 2006, CNS drugs.
[36] K. Midha,et al. Enantioselective Pharmacokinetics of dl-threo-Methylphenidate in Humans , 2004, Pharmaceutical Research.
[37] D. Abernethy,et al. Pharmacokinetics and Clinical Effectiveness of Methylphenidate , 1999, Clinical pharmacokinetics.